Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
|Articles|October 9, 2014
Unlocking the True Value of Big Data
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more...
Advertisement
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more…
Advertisement
Related to this article
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
4
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
5